Patents by Inventor Douglas D Lemon

Douglas D Lemon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7211560
    Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.
    Type: Grant
    Filed: December 29, 2003
    Date of Patent: May 1, 2007
    Assignees: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
  • Patent number: 7049406
    Abstract: The invention relates to novel recombinant hemoglobins having reduced nitric oxide scavenging and/or increased high soluble expression. The invention further relates to methods of increasing the soluble expression of recombinant hemoglobin by adding exogenous hemin in molar excess of the heme binding sites of recombinant hemoglobin.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: May 23, 2006
    Assignees: Baxter Biotech Technology SARL, William Marsh Rice University
    Inventors: Michael J Weickert, Christopher B Glascock, Antony J Mathews, Douglas D Lemon, Daniel H Doherty, John S Olson
  • Publication number: 20040259769
    Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.
    Type: Application
    Filed: December 29, 2003
    Publication date: December 23, 2004
    Applicants: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
  • Patent number: 6670323
    Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: December 30, 2003
    Assignees: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
  • Publication number: 20030017537
    Abstract: The invention relates to novel recombinant hemoglobins having reduced nitric oxide scavenging and/or increased high soluble expression. The invention further relates to methods of increasing the soluble expression of recombinant hemoglobin by adding exogenous hemin in molar excess of the heme binding sites of recombinant hemoglobin.
    Type: Application
    Filed: March 27, 2002
    Publication date: January 23, 2003
    Applicant: Baxter Biotech Technology SARL William Marsh Rice Univ.
    Inventors: Michael J. Weickert, Christopher B. Glascock, Antony J. Mathews, Douglas D. Lemon, Daniel H. Doherty, John S. Olson
  • Patent number: 6455676
    Abstract: The invention relates to novel recombinant hemoglobins having reduced nitric oxide scavenging and/or increased high soluble expression. The invention further relates to methods of increasing the soluble expression of recombinant hemoglobin by adding exogenous hemin in molar excess of the heme binding sites of recombinant hemoglobin.
    Type: Grant
    Filed: April 25, 2000
    Date of Patent: September 24, 2002
    Assignees: Baxter Biotech Technology SARL, William Marsh Rice Univerisity
    Inventors: Michael J. Weickert, Christopher B. Glascock, Antony J. Mathews, Douglas D. Lemon, Daniel H. Doherty, John S. Olson